IP36-13: Adding upfront, perioperative durvalumab versus adopting risk-adapted adjuvant nivolumab? Cost-effectiveness analysis of competing treatment strategies for cisplatin-eligible muscle-invasive bladder cancer in the era of immune checkpoint inhibito